Skip to main content
Caplight Logo









EpicentRx

EpicentRx

Private
La Jolla, CaliforniaHealthcare & Life Scienceshttps://www.epicentrx.com/

Last Round

Grant

Sep 17, 2024

Total Funding Raised

$47.31M

Company Overview

EpicentRx is a biotechnology company that develops a next-generation immunotherapy platform and small molecule therapies to treat cancer, inflammatory diseases, and other conditions with unmet medical needs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

biopharmaceuticaloncolytic virussmall moleculecancer therapyimmunotherapyradiosensitizerdrug developmentclinical trialsbiotechtumor microenvironmentmedical countermeasuresdrug delivery systemoncology researchtherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EpicentRx Comparables

Compare EpicentRx with similar companies based on industry and business-model similarity.

EpicentRx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
TILT Biotherapeutics
81%
BioEclipse Therapeutics
79%
Lokon Pharma
79%

EpicentRx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 17, 2024
GrantNov 29, 2022
GrantJul 12, 2022
DebtJan 6, 2021
Series DNov 14, 2019

Key People

Founding team and executive leadership

Tony Reid

Chief Executive Officer

Executive Team

EpicentRx Filings

Explore SEC and related filing metadata, where available.

EpicentRx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about EpicentRx's valuation, stock price, and market status.

Is EpicentRx a public or private company?

EpicentRx is a private company.

What is the current stock price of EpicentRx?

EpicentRx is a private company with no public stock price. No recent secondary market data is available.

How much is EpicentRx worth (valuation)?

Valuation information for EpicentRx is not publicly available.

Can I buy EpicentRx stock?

EpicentRx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was EpicentRx's last funding round?

EpicentRx's most recent funding round was Grant on July 12, 2022.

Who are the main investors in EpicentRx?

Key investors in EpicentRx include Silicon Valley Bank.

Will EpicentRx IPO soon?

No public IPO plans have been announced for EpicentRx.

How can I track EpicentRx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor EpicentRx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLa Jolla, California
Employee Range16
Year Founded2010
Last FundingSep 17, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?